Treace Medical Concepts to Showcase Innovations at AOFAS Meeting

PONTE VEDRA, Fla., Sept. 15, 2026 /CourierPR/ -- Treace Medical Concepts, Inc., a company at the forefront of bunion and foot & ankle treatment solutions, is set to showcase its latest advancements and clinical data at the upcoming American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Seattle, Washington, from September 16 to 19, 2026.

The company, known for its innovative 3D bunion correction technologies, will present several new product innovations aimed at enhancing its market leadership. Among the highlights are the Lapiplasty® Lightning™ System, a next-generation instrumentation that accompanies the SpeedTMT® implant technology, designed to provide surgeons with precise control over 3D bunion correction while streamlining the surgical process.

Additionally, Treace will introduce the Tailorplasty™ MIS Tailor’s Bunion System, a minimally invasive solution for treating tailor’s bunions, or "bunionettes," which affect approximately 5-10% of the adult population. This system offers a faster and more efficient approach to addressing this common foot condition.

In addition to these bunion correction technologies, Treace will also present the Treace™ X-ray App, a cloud-based software tool that enables surgeons to make radiographic measurements in foot and ankle X-rays, providing them with valuable anatomical data at their fingertips.

Expanding its reach into the mid and hindfoot markets, Treace will introduce several new innovations. The SuperBite™ Fully-Threaded Compression Screws are designed to reduce steps and save time in fusion and osteotomy procedures, addressing a broad range of foot & ankle applications. The HyperPlate™ XM Dynamic Compression Locking Implant, a highly stable fixation construct, combines locking screws and dynamic compression to promote fusion in the larger bones of the midfoot and hindfoot. The CartiBlaster™ Powered Joint Prep instruments offer fast and controlled cartilage removal and joint preparation in fusion procedures throughout the midfoot and hindfoot. Lastly, the VitaFuse™ Bioactive Glass Graft, a new synthetic bone graft technology, complements Treace’s growing biologics portfolio.

Treace will also present clinical data from landmark studies, including the 5-year ALIGN3D® Lapiplasty® clinical study, which will be presented on September 18 at 8:45 AM Pacific Standard Time. The study will focus on the radiographic, clinical, and patient-reported outcomes of a prospective multicenter study of triplanar tarsometatarsal arthrodesis with early weightbearing. Another study, the MTA3D® Adductoplasty® clinical study, will be presented on September 17 at 4:00 PM Pacific Standard Time, focusing on the radiographic and patient-reported outcomes following combined metatarsus adductus and hallux valgus correction with early weightbearing. The SPRINT™ SpeedPlate® observational clinical study will be presented as an audio poster, discussing radiographic and patient-reported outcomes following joint arthrodesis in the foot using a novel, dynamic compression implant system.

With a mission to be the recognized leader in the surgical treatment of bunions and other foot & ankle conditions, Treace continues to innovate and expand its product portfolio to better serve the needs of surgeons and patients. The company’s commitment to advancing surgical techniques and technologies is evident in its ongoing research and development efforts, as well as its participation in the AOFAS Annual Meeting.